Intracardiac thrombosis following intravenous zoledronate treatment in a child with steroid-induced osteoporosis
| Autor: | Samantha J. Case, Rebecca J. Moon, Tara Bharucha, Justin H. Davies |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Journal of Pediatric Endocrinology and Metabolism. 36:327-330 |
| ISSN: | 2191-0251 0334-018X |
| DOI: | 10.1515/jpem-2022-0475 |
| Popis: | Objectives Bisphosphonates are used in childhood osteoporosis but can cause an acute phase reaction (APR) and hypocalcemia. We present a child with cardiac thrombosis following zoledronate, a previously unreported complication. Case presentation An 11-year-old with Duchenne muscular dystrophy and steroid-induced osteoporosis presented 48 h after first zoledronate infusion with fever, tachycardia, tachypnoea and hypoglycaemia. This was managed as acute adrenal crisis and possible sepsis. He also had hypocalcemia, hypophosphatemia, hyponatraemia and hypokalaemia. Echocardiography performed due to persistent chest pain and tachycardia revealed a left ventricular thrombus. Conclusions Potential causes for intracardiac thrombosis in this patient include ventricular dysfunction due to acute adrenal crisis or electrolyte disturbance, and hypercoagulability due to the APR. Echocardiography should be considered in children with acute cardiovascular compromise following zoledronate. Stress-dose steroids to cover the APR and a reduced starting dose of zoledronate might have reduced the risk of this complication. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|